Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "peptides"

66 News Found

IMCD unveils future of beauty at In-Cosmetics Latin America 2025
News | October 07, 2025

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends


A. P. Rameswara Rao appointed National President of BDMAI
People | October 03, 2025

A. P. Rameswara Rao appointed National President of BDMAI

A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries


Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Clinical Trials | September 16, 2025

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity


AbbVie to invest $195 million to expand API manufacturing in North Chicago
News | August 16, 2025

AbbVie to invest $195 million to expand API manufacturing in North Chicago

The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Bachem expands multi-site production capacities to meet rising demand
News | June 25, 2025

Bachem expands multi-site production capacities to meet rising demand

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland


Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
News | April 29, 2025

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides


CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein


Granules India completes acquisition of Senn Chemicals
News | April 11, 2025

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services